IVVD
NASDAQ · Biotechnology
Invivyd Inc
$1.59
+0.16 (+11.19%)
Open$1.48
Previous Close$1.43
Day High$1.59
Day Low$1.45
52W High$3.07
52W Low$0.46
Volume—
Avg Volume2.64M
Market Cap446.17M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,250.9% upside
Current
$1.59
$1.59
Target
$21.48
$21.48
$15.01
$21.48 avg
$34.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 59.33M | 178.19M | 160.29M |
| Net Income | -397,200,155 | 4.92M | 3.11M |
| Profit Margin | -669.4% | 2.8% | 1.9% |
| EBITDA | -410,141,791 | 6.39M | 5.91M |
| Free Cash Flow | — | 2.75M | 2.88M |
| Rev Growth | — | +11.2% | +5.5% |
| Debt/Equity | — | 0.18 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |